Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCI699 in Cushing's Disease
NCT01331239Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2011
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of osilodrostat in Cushing's disease (CD), sponsored by Novartis. Started Mar 2011; status: completed.
02
Drugs
osilodrostat
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT01331239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01331239.